Joseph Gauta, MD
Obstetrics & Gynecology · Naples, FLNPI 1619966769
Payments from drug & device makers
Across 238 payments — averaging $643.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$112K
- Boston Scientific$29K
- Laborie Medical Technologies Corp.$6K
- Coloplast$2K
- Caldera Medical, Inc$946
- AbbVie$392
- plus $2K from 28 others
Across 3 payments — averaging $2079.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$6K
What the payments were for
- Consulting fees$3,39525%
- Speaking & faculty fees$3,91029%
- Food & beverage$6,34846%
- Education$470%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 86 | $112,447 |
| Boston Scientific | 12 | $29,483 |
| Laborie Medical Technologies Corp. | 17 | $5,718 |
| Coloplast | 15 | $2,183 |
| Caldera Medical, Inc | 13 | $946 |
| AbbVie(2 entities) | 22 | $392 |
| Astellas Pharma US Inc | 11 | $266 |
| Medtronic(2 entities) | 5 | $202 |
| Baudax Bio Inc. | 8 | $157 |
| Escala Medical Inc. | 3 | $156 |
| Bluewind Medical | 3 | $125 |
| Valencia Technologies Corporation | 2 | $108 |
| Pfizer | 6 | $105 |
| Intuitive Surgical | 1 | $76 |
| Kowa Pharmaceuticals America, Inc. | 3 | $69 |
| Coopersurgical, Inc. | 3 | $65 |
| Therapeuticsmd, Inc. | 3 | $57 |
| Urovant Sciences Inc | 3 | $55 |
| Hologic Sales And Service, LLC | 2 | $54 |
| Minerva Surgical, Inc | 3 | $48 |
| 180 Medical, Inc. | 2 | $48 |
| Sumitomo Pharma America, Inc. | 2 | $35 |
| Lupin Inc. | 2 | $34 |
| Conmed Corporation | 1 | $29 |
| Femselect Inc. | 1 | $27 |
| Clinical Innovations, LLC | 1 | $25 |
| Davol Inc. | 1 | $25 |
| Abbott | 1 | $25 |
| Teleflex LLC | 1 | $25 |
| Provepharm Inc. | 1 | $18 |
| Myovant Sciences Inc. | 1 | $18 |
| Dysis Medical, Inc. | 1 | $14 |
| Meditrina | 1 | $12 |
| Mission Pharmacal Company | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$153,058 in reported general payments places this provider in the 95th percentile of 2,438 obstetrics & gynecology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 151 | $157,198 |
| GemtesaVibegron | 96 | $100,774 |
| Estradiol | 148 | $9,167 |
| Methenamine Hippurate | 48 | $4,877 |
| Oxybutynin Chloride ErOxybutynin Chloride | 82 | $2,032 |
| Tolterodine Tartrate ErTolterodine Tartrate | 17 | $1,350 |
| Solifenacin Succinate | 18 | $984 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $894 |
| Oxybutynin Chloride | 23 | $541 |
| Cefdinir | 22 | $429 |
| Cephalexin | 22 | $277 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 30 | $145 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 33 | $133 |
| Tamsulosin Hcl | 11 | $119 |
| Amitriptyline Hcl | 11 | $116 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $266 | $157,198151 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $35 | $100,77496 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,438 obstetrics & gynecology providers in Florida.
Other obstetrics & gynecology in Naples
- Samuel LedermanLake Worth$13.4M
- Richard MyersJacksonville$2.7M
- Guillermo LievanoMiami$2.5M
- Steven McCarusCelebration$2.3M
- Samuel WolfPanama City$2.1M
- Rafael Garcia-OcasioHialeah$2M
- Douglas MoffettLeesburg$1.7M
- Harvey GlasserAventura$1.6M
- Jorge PandoMiami Lakes$1.5M
- Victoria BedellMiami$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.